Jefferies raised the firm’s price target on Structure Therapeutics (GPCR) to $125 from $79 and keeps a Buy rating on the shares, calling the recent positive Phase 2b data for aleniglipron a “solid win.” The firm sees Structure having a “best-in-class small molecule” oral GLP1 with the most de-risked clinical data and advanced development stage, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Announces $650 Million Public Offering
- Structure Therapeutics 8.5M share Spot Secondary priced at $65.00
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- Why is Biotech Stock iBio Up over 50%?
- Promising Outlook for Structure Therapeutics’ Aleniglipron: Buy Rating Affirmed Amid Strong Phase 2b Results and Market Potential